Ganoderol B is a lanostane-type triterpenoid isolated from the medicinal mushroom *Ganoderma lucidum* (Lingzhi or Reishi). It is characterized by a tetracyclic triterpenoid skeleton with specific hydroxyl and carbonyl substitutions, contributing to its biological activity. This compound is a key bioactive constituent of *Ganoderma lucidum*, which has been used in traditional medicine for centuries. Research indicates that Ganoderol B exhibits significant pharmacological properties, including potent anti-inflammatory, antioxidant, and notably, anti-diabetic effects. Studies have shown it can inhibit α-glucosidase activity, suggesting potential for managing postprandial blood glucose levels. It is also investigated for its hepatoprotective and neuroprotective activities. Due to its origin and multifaceted bioactivity profile, Ganoderol B is primarily studied as a lead compound or active pharmaceutical ingredient (API) in the development of nutraceuticals and herbal medicines. It serves as a standard reference material in the quality control of *Ganoderma*-based products and in pharmacological research exploring natural product-based therapies for metabolic and age-related disorders.